---
title: "603229.SH (603229.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603229.SH/news.md"
symbol: "603229.SH"
name: "603229.SH"
parent: "https://longbridge.com/en/quote/603229.SH.md"
datetime: "2026-05-20T22:59:15.372Z"
locales:
  - [en](https://longbridge.com/en/quote/603229.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603229.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603229.SH/news.md)
---

# 603229.SH (603229.SH) — Related News

### [](https://longbridge.com/en/news/285295879.md)
*2026-05-06T01:53:13.000Z*
> The A-share innovative drug sector has fluctuated and strengthened, with TONGHUA GOLDEN-HORSE hitting the daily limit, O

### [Ausun Pharm released its 2025 annual performance, with a net profit attributable to the parent company of 131 million yuan, a year-on-year decrease of 36.86%](https://longbridge.com/en/news/284340292.md)
*2026-04-28T09:09:45.000Z*
> Ausun Pharm released its 2025 annual report, with revenue of 793 million yuan, a year-on-year decrease of 0.32%; net pro

### [Ausun Pharm released its first-quarter performance, with a net profit attributable to the parent company of 96.66 million yuan, a year-on-year decrease of 18.91%](https://longbridge.com/en/news/284339580.md)
*2026-04-28T09:04:03.000Z*
> Ausun Pharm released its Q1 2026 performance, with revenue of 309 million yuan, a year-on-year increase of 0.66%; net pr

### [Ausun Pharm received the approval notice for the listing application of the chemical raw material drug Lurasidone Hydrochloride](https://longbridge.com/en/news/281161375.md)
*2026-03-31T09:37:32.000Z*
> Ausun Pharm recently received the notice of approval for the marketing application of the chemical raw material drug, Ru

### [Ausun Pharm's cooperative product tofacitinib citrate tablets has obtained overseas listing approval](https://longbridge.com/en/news/274934235.md)
*2026-02-05T07:50:02.000Z*
> Ausun Pharm announced that its partner STADA's subsidiary Spirig HealthCare AG has obtained marketing authorization from

### [Ausun Pharm: Completed the repurchase of 0.63% of the company's shares](https://longbridge.com/en/news/273492349.md)
*2026-01-23T09:13:58.000Z*
> Ausun Pharm announced that as of January 23, 2026, the company has repurchased a total of 5.2012 million shares through 

### [Ausun Pharm: Pablociclib active pharmaceutical ingredient and Dapagliflozin active pharmaceutical ingredient have obtained marketing authorization](https://longbridge.com/en/news/271079582.md)
*2025-12-30T08:27:16.000Z*
> Ausun Pharm recently announced that it has obtained approval from the National Medical Products Administration for the m

### [Ausun Pharm: Has repurchased a total of 5.2012 million shares, amounting to 50.006 million yuan](https://longbridge.com/en/news/263960530.md)
*2025-11-03T07:54:22.000Z*
> Ausun Pharm announced that as of October 31, 2025, the company has repurchased a total of 5.2012 million shares, with a